Company Overview

Product Focused Company Creating New Combination Medicines

CombinatoRx, Incorporated is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs. In less than six years, we have discovered and advanced into clinical trials a portfolio of six product candidates targeting multiple immuno-inflammatory diseases and cancer, at a total investment, including development of our proprietary screening technology, of less than $50 million.

Systems Biology Approach Targets Multiple Disease Pathways

We are developing our combination drugs in response to the understanding that many diseases affect the body through multiple biological pathways. Traditional drug discovery has focused on agents that target a single biological pathway. We believe that by targeting multiple pathways, our combination drug candidates may create synergistic therapeutic effects, which could result in improved treatments for many diseases.